Come up with a name for your new list and we'll add to it:
Esperion Therapeutics was acquired by
Pfizer on February 16, 2004.
Esperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase i…